ASCO 2022: Breast cancer highlights

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Can we afford the cost of newly approved targeted therapeutics in the management of breast cancer globally?

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma